FINWIRES · TerminalLIVE
FINWIRES

Pet Industry Bitten by Inflation May Make Attractive Takeover Targets

By
Pet Industry Bitten by Inflation May Make Attractive Takeover Targets

Rising prices and reduced affordability are leading to declining pet ownership, taking a bite out of industry valuations and potentially signaling a coming wave of consolidation, according to equity analysts.

The share of US households with a pet has declined in the past two years by about 2.6%, and dog adoptions have fallen, according to Bank of America research. The cost of veterinary care has also risen, adding to pet owners' concerns.

"It's clear that people still love their pets, but the cost associated with owning a pet is increasingly shaping household budgeting decisions, and we see that really clearly in our data," Taylor Bowley, the Bank of America Institute economist who wrote the research note, said in an interview with. "Ownership every day is getting more expensive."

Shares of Chewy (CHWY) and Trupanion (TRUP) are both down about 50% in the past year, and Bark (BARK) is off by 43%. PetMed Express (PETS) is down 41%, Freshpet (FRPT) has lost 22%, and Petco Health and Wellness (WOOF) has dropped 7.8%.

Decreased valuations will likely make pet companies, which have recently become e-commerce companies as more consumers buy food and supplies for their furry friends online, attractive targets for companies seeking acquisitions in the segment.

Bank of America equity analyst Michael McGovern said that while it's hard to predict M&A activity, the share price drop across the pet sector within the e-commerce industry is notable.

"These are some of the most attractive valuations that we've seen across recent - call it 10 years - for the e-commerce sector specifically," he said in an interview.

Recent M&A activity in the pet sector includes two deals by Chewy in the animal health area - an April offer to acquire Modern Animal to expand its veterinary care services and a deal from October 2025 for SmartPak Equine, which is an online seller of horse supplies and supplements. In February, Elanco bought AHV International BV for $380 million to expand its business in the Netherlands.

Freshpet is a long-term acquisition candidate, Oppenheimer analyst Rupesh Parikh said in a March report. The maker of refrigerated cat and dog food didn't respond immediately to an email seeking comment.

Pet food manufacturers and retailers have shown a growing interest in the fresh pet food category. Freshpet's leading product portfolio and position in the fresh segment are making it an attractive target, and the stock has "downside support" precisely because of its takeout potential, Parikh said.

M&A in the pet segment, as with most other sectors, comes with certain risks for not just industry players but also consumers. That can be seen in consolidation in the veterinary services industry, Bank of America said. About 25% to 30% of US veterinary practices, which represent roughly three-fourths of all specialty clinics, are now owned by large corporations or private equity firms. That's drawn the attention of some members of Congress.

"Such consolidation can erode competition, elevate prices, and weaken service quality, ultimately reducing consumer choice," BofA economist Bowley said in the note.

Still, not everybody is convinced that the pet sector is seeing any sort of downturn.

Jeff Simmons, the chief executive at Elanco Animal Health (ELAN), said the company has researched pet health spending that shows no decline.

"The resiliency and the willingness to spend on pet health, maybe not toys or premium dog food, but on pet health, is actually the same or increasing during these economic times," Simmons said in an interview with.

Only 5.2% of pet owners in a TD Cowen survey conducted in May said they plan to spend less on pets, pet products, or veterinary services in the next six months, down from 5.4% in January. More than half - 55% -- said they expect spending to be unchanged, and 40% will spend more.

Shares of Elanco doubled last year and are up 9% year to date as of June 26.

"We're seeing a durability at a time of a consumer pullback on a lot of stuff," Simmons said. "We're not seeing it in our industry, and I will tell you, we're not seeing it in our results."

Morgan Stanley analysts said in a recent note that the pet industry will remain in neutral amid inflation that drives ownership costs higher.

"The pet industry is entering a more mature growth phase after COVID-related outperformance and a subsequent inflationary period, which has continued to date," the analysts said in a May 29 note to investors.

The Bank of America note showed that spending on pets dropped the most among lower-income households and younger pet owners. If prices continue to rise, veterinarians will likely have to rely on repeat visitors to offset economic trends.

"If current macro headwinds persist, veterinary pricing will become increasingly harder for everyday pet owners to absorb, accelerating pressure on visit volumes through deferred care," the bank said.

Matthew Leising

Price: $24.71, Change: $+0.62, Percent Change: +2.57%

Related Articles

Australia's Perpetual Turns Down AU$2.45 Billion EQT Buyout Bid
US Markets

Australia's Perpetual Turns Down AU$2.45 Billion EQT Buyout Bid

Australian investment fund Perpetual (ASX:PPT) has turned down a takeover approach from Swedish private equity firm EQT AB, saying the proposal undervalued the financial services company, according to a Wednesday press release.Under the proposal, EQT-controlled Windflower Pte Limited offered to acquire all of Perpetual's shares for AU$21.64 apiece in cash, valuing the company at about AU$2.45 billion."The indicative proposal was highly conditional and did not adequately represent fair value for Perpetual shareholders in the context of a change of control transaction," the company said in a statement.The approach comes after Perpetual terminated an AU$2.2 billion deal with private equity firm KKR in 2025 to sell its wealth management and corporate trust businesses.The transaction was scrapped after an independent expert concluded it was not in the best interests of shareholders following an adverse tax ruling.Perpetual said it would instead pursue a separate sale of its wealth management business.The investment manager subsequently agreed to sell its wealth management business to Bain Capital for an upfront cash payment of AU$500 million, with additional performance-linked payments of up to AU$50 million.The company said the proceeds would be used to reduce debt and support growth in its asset management and corporate trust businesses.The latest proposal adds to a string of takeover attempts for the investment manager.Perpetual rejected an AU$1.7 billion bid from a consortium that included Regal Partners in 2022, before turning down an AU$3.1 billion offer from its largest shareholder, Washington H. Soul Pattinson, the following year.

ASX:PPT
Update: Alibaba, US Payments Partner to Pay $600 Million in Drug-Import Probe
US Markets

Update: Alibaba, US Payments Partner to Pay $600 Million in Drug-Import Probe

(Updates to remove the seeking comment line in the 9th paragraph, as Alibaba has since responded)Alibaba Group (HKG:9988) and its US payments processor, AUS Merchant Services, agreed to pay a combined $600 million to resolve an investigation by the US Justice Department into illegal pharmaceutical sales on the company's e-commerce platforms.The Chinese tech and e-commerce firm admitted that between January 2016 and December 2024, it failed to prevent roughly 80,000 product sales on Alibaba.com and AliExpress.com that involved unlawful imports of pharmaceuticals, controlled substances, listed chemicals and pill presses, according to a Wednesday notice from the Justice Department.In a statement issued to, Alibaba described the settlement as a "mutually satisfactory resolution with U.S. regulators.""This settlement reflects a thorough regulatory process with Alibaba's full cooperation and our commitment to best-in-class standards of control, policies, and measures against non-compliant product sales."The products involved in the investigation have a combined gross merchandise value exceeding $200 million, the DOJ said, adding that federal agents made more than 40 undercover purchases of illegal drugs and counterfeiting equipment during the probe.Separately, AUS admitted that from January 2020 to December 2023, it accepted US dollar-denominated wire and credit-card payments on behalf of overseas Alibaba merchants.Under a non-prosecution agreement, Alibaba will pay a $125 million criminal penalty and forfeit $200 million, while AUS, formerly known as Alipay US, will pay an $85 million penalty and forfeit $190 million.First Assistant U.S. Attorney Charles C. Calenda for the District of Rhode Island called it "the largest monetary settlement in the history of the District of Rhode Island."Assistant Attorney General Brett A. Shumate of the Justice Department's Civil Division, said, "Companies operating online marketplaces - whether based in the United States or abroad - must implement appropriate safeguards to prevent bad actors from exploiting their platforms. If they fail to do so, the Department will hold them accountable."The settlement marks the latest US action against Alibaba after the US Department of Defense in June added the company to its list of "Chinese military companies" under Section 1260H of the National Defense Authorization Act, alongside Baidu (HKG:9888), BYD (HKG:1211, SHE:002594), Nio (HKG:9866), WuXi AppTec (HKG:2359, SHA:603259), Robosense Technology (HKG:2498) and more.Last week, Alibaba sued the Pentagon, seeking to overturn the designation and accusing the department of acting without factual basis or fair process in branding it as a threat to national security."The determinations have no basis in fact or law... To label Alibaba a 'Chinese military company' is to brand it an instrument of the Chinese military and a threat to US national security," Alibaba wrote.

HKG:9988
Alibaba, US Payments Partner to Pay $600 Million in Drug-Import Probe
US Markets

Alibaba, US Payments Partner to Pay $600 Million in Drug-Import Probe

Alibaba Group (HKG:9988) and its US payments processor, AUS Merchant Services, agreed to pay a combined $600 million to resolve an investigation by the US Justice Department into illegal pharmaceutical sales on the company's e-commerce platforms.The Chinese tech and e-commerce firm admitted that between January 2016 and December 2024, it failed to prevent roughly 80,000 product sales on Alibaba.com and AliExpress.com that involved unlawful imports of pharmaceuticals, controlled substances, listed chemicals and pill presses, according to a Wednesday notice from the Justice Department.In a statement issued to, Alibaba described the settlement as a "mutually satisfactory resolution with U.S. regulators.""This settlement reflects a thorough regulatory process with Alibaba's full cooperation and our commitment to best-in-class standards of control, policies, and measures against non-compliant product sales."The products involved in the investigation have a combined gross merchandise value exceeding $200 million, the DOJ said, adding that federal agents made more than 40 undercover purchases of illegal drugs and counterfeiting equipment during the probe.Separately, AUS admitted that from January 2020 to December 2023, it accepted US dollar-denominated wire and credit-card payments on behalf of overseas Alibaba merchants.Under a non-prosecution agreement, Alibaba will pay a $125 million criminal penalty and forfeit $200 million, while AUS, formerly known as Alipay US, will pay an $85 million penalty and forfeit $190 million.First Assistant U.S. Attorney Charles C. Calenda for the District of Rhode Island called it "the largest monetary settlement in the history of the District of Rhode Island."Alibaba did not immediately respond to' request for comment.Assistant Attorney General Brett A. Shumate of the Justice Department's Civil Division, said, "Companies operating online marketplaces - whether based in the United States or abroad - must implement appropriate safeguards to prevent bad actors from exploiting their platforms. If they fail to do so, the Department will hold them accountable."The settlement marks the latest US action against Alibaba after the US Department of Defense in June added the company to its list of "Chinese military companies" under Section 1260H of the National Defense Authorization Act, alongside Baidu (HKG:9888), BYD (HKG:1211, SHE:002594), Nio (HKG:9866), WuXi AppTec (HKG:2359, SHA:603259), Robosense Technology (HKG:2498) and more.Last week, Alibaba sued the Pentagon, seeking to overturn the designation and accusing the department of acting without factual basis or fair process in branding it as a threat to national security."The determinations have no basis in fact or law... To label Alibaba a 'Chinese military company' is to brand it an instrument of the Chinese military and a threat to US national security," Alibaba wrote.

HKG:9988